Emulating Hypothetical Target Trials of the Broad-Spectrum T2 Biologic Dupilumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emulating Hypothetical Target Trials of the Broad-Spectrum T2 Biologic Dupilumab

Published:2024-07 Issue:7 Volume:21 Page:1111-1112
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Akenroye Ayobami¹^ORCID,Keet Corinne²

Affiliation:

1. Brigham and Women’s HospitalBoston, Massachusetts

2. University of North CarolinaChapel Hill, North Carolina

Funder

ALA/ATS/CHEST Foundation Respiratory

National Institute on Minority Health and Health Disparities

Brigham and Women’s Hospital Minority

Publisher

American Thoracic Society

Link

https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.202403-268LE

Reference6 articles.

1. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis

2. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation

3. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

4. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP